Morning Movers 11/21: (GEDU) (VRUS) (INHX) (BSDM) Higher; (BIOF) (ALXA) (PEIX) (HNSN) Lower

FREE Breaking News Alerts from StreetInsider.com!

GEDU Hot Sheet

Overall Analyst Rating:
NEUTRAL (

Global Education & Technology Group Limited (Nasdaq: GEDU) 97.4% HIGHER; has entered into a definitive agreement and plan of merger with Pearson plc, a wholly owned indirect subsidiary of Pearson (NYSE: PSO), pursuant to which Pearson would acquire all of the outstanding shares of the Company for a total value of approximately $294 million.

Pharmasset (Nasdaq: VRUS) 85% HIGHER; Gilead Sciences to acquire Pharmasset for $137/share.

Inhibitex (Nasdaq: INHX) 29% HIGHER; likely trading higher amid the Pharmasset/Gilead deal.

BioFuel Energy (Nasdaq: BIOF) 16.5% LOWER; traders are taking profits this week following a more than 60 percent runup last week.

Alexza Pharma (Nasdaq: ALXA) 15.4% LOWER; pushing toward a technical level just over $1 today.

BSD Medical Corporation (Nasdaq: BSDM) 13.7% HIGHER; has obtained Humanitarian Device Exemption (HDE) marketing approval for the BSD-2000 Hyperthermia System (BSD-2000) from the U.S. Food and Drug Administration (FDA). Click here to see the full release.

Pacific Ethanol (Nasdaq: PEIX) 13.4% LOWER; with crude crossing $100 per barrel last week, shares of the stock jumped nearly 78 percent since last Friday. Traders are likely taking profits today.

Hansen Medical (Nasdaq: HNSN) 13.3% LOWER; correcting today following a late-day 16 percent run up at the end of Friday.

Focus Media (Nasdaq: FMCN) 12.8% LOWER; leading US-listed China-based stocks lower this morning. The company reported Q3 results and guided on Thursday of last week.

Zillow (Nasdaq: Z) 11.8% LOWER; falling on heavy volume today.

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) 11.4% HIGHER; the U.S. Food and Drug Administration (FDA) has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams (mg) every four weeks (monthly) for the first 12 weeks, followed by 2 mg every eight weeks (2 months). The stock was upgraded to Neutral at BofA this morning.

Gilead Sciences (Nasdaq: GILD) 10.7% LOWER; traders selling following news of a massive bid for Pharmasset.

Great Basin Gold (NYSE: GBG) 9.2% LOWER; Raymond James downgraded the stock from Outperform to Market Perform, price target lowered from $3.70 to $2.15.

Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!